Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs

Table 3 Normalization with bodyweight of Motion (M)-mode parameters of myxomatous mitral valve degenerative dogs pre- and post-treatment in the control and treatment groups

M-mode Parameter	Control group (n = 11)		Treatment group (n = 18)		95% prediction interval (cm) [31]
M-mode Parameter	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	95% prediction interval (cm) [31]
LA diameter (cm)	1.11 ± 0.05	1.06 ± 0.14	1.25 ± 0.21	1.19 ± 0.19	0.59-0.97
AO diameter (cm)	0.74 ± 0.10	0.76 ± 0.09	0.75 ± 0.08	0.73 ± 0.10	0.63-0.96
IVSDN (cm)	0.48 ± 0.1	0.45 ± 0.08	0.41 ± 0.09	0.42 ± 0.1	0.29-0.59
LVIDdN (cm)	1.53 ± 0.28	1.60 ± 0.25	1.69 ± 0.3	1.65 ± 0.32	1.27-1.85
LVPWdN (cm)	0.49 ± 0.14	0.47 ± 0.07	0.44 ± 0.09	0.43 ± 0.07	0.29-0.60
IVSsN (cm)	0.64 ± 0.12	0.68 ± 0.16	0.65 ± 0.11	0.64 ± 0.13	0.43-0.79
LVIDsN (cm)	0.85 ± 0.21	0.79 ± 0.15	0.81 ± 0.16	0.80 ± 0.23	0.71-1.26
LVPWsN (cm)	0.69 ± 0.09	0.75 ± 0.11	0.75 ± 0.13	0.70 ± 0.12	0.48-0.87

Values are presented as mean ± SD. LA left atrium, AO Aortic root, IVSdN normalized interventricular septum thickness end-diastole, LVIDdN normalized left ventricular internal diameter end-diastole, LVPWdN normalized left ventricular posterior wall end diastole, IVSsN normalized interventricular septum thickness end systole, LVIDsN normalized left ventricular internal diameter end systole, LVPWsN normalized left ventricular posterior wall end-systole

ISSN: 1746-6148